

## Special Issue

# Advances in Nanomedicine for Disease Treatment and Diagnosis

### Message from the Guest Editors

Dear Colleague, Nanomedicine, integrating nanotechnology, biology and medicine, has emerged for providing better disease treatments and more precise diagnosis. In the recent 20 years, various nanomedicines have been developed by engineering nanomaterials to deliver therapeutic/imaging agents such as drugs, proteins, peptides, imaging probes and photosensitizers to targeted tissues and cells. Several innovative therapeutic strategies, such as personalized nanomedicine, imaging-guided nanomedicine, and combination therapies (photothermal therapy, photodynamic therapy, sonodynamic therapy, and immunotherapy) are making remarkable progress, achieving the goals of early diagnosis and improving treatment efficiency. So far, >20 nanomedicines have been approved by US Food and Drug Administration (FDA) and used in the clinic, and more are in clinical trials, bringing about the revolution of conventional medicine.

---

### Guest Editors

Dr. Li Li

Dr. Run Zhang

Prof. Dr. Zhiping Xu

Dr. Anjaneyulu Dirisala

Dr. Yuki Mochida

---

### Deadline for manuscript submissions

closed (30 September 2023)



## Biomedicines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.9  
CiteScore 7.8  
Indexed in PubMed



[mdpi.com/si/100288](https://mdpi.com/si/100288)

*Biomedicines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)

[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)





# Biomedicines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.9  
CiteScore 7.8  
Indexed in PubMed



[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)



## About the Journal

### Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

---

### Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA

2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).